Anika Therapeutics (NASDAQ:ANIK - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Friday, May 9th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $27.50 million for the quarter.
Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last released its earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.13). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. The company had revenue of $30.60 million during the quarter, compared to analysts' expectations of $29.00 million. On average, analysts expect Anika Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Anika Therapeutics Stock Performance
Shares of ANIK stock opened at $14.46 on Friday. The firm has a market capitalization of $207.37 million, a price-to-earnings ratio of -2.17 and a beta of 0.82. The company has a 50 day moving average price of $15.20 and a 200 day moving average price of $16.99. Anika Therapeutics has a one year low of $12.83 and a one year high of $29.12.
Wall Street Analysts Forecast Growth
Several research analysts recently weighed in on ANIK shares. Barrington Research cut their target price on Anika Therapeutics from $25.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, March 13th. StockNews.com upgraded Anika Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Finally, B. Riley assumed coverage on Anika Therapeutics in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 target price for the company.
Check Out Our Latest Research Report on ANIK
Anika Therapeutics Company Profile
(
Get Free Report)
Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Anika Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anika Therapeutics wasn't on the list.
While Anika Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
